Approach to Partnering

Oxagen’s strategy is to develop its drug programmes for asthma through to Phase III trials, working thereafter with partners for further development and commercialisation, and to broaden its pipeline through collaborations addressing other indications.

First, Oxagen intends to form partnerships for global or regional development of its lead once-a day-oral molecule for asthma (CRTH2 antagonist OC000459). The molecule is currently in Phase IIb clinical studies and shows strong efficacy in allergic asthmatics along with an excellent safety profile.

Second, Oxagen welcomes opportunities to broaden the focus of its CRTH2 antagonist programme. It seeks partnerships with specialist organisations to develop its drug candidates outside of asthma. The company has a portfolio of patent protected, potent and specific compounds including optimized leads, a clinic-ready backup compound and OC000459 with potential in a broad range of allergic indications including allergic rhinitis, allergic conjunctivitis, atopic dermatitis and eosinophilic esophagitis.

Third, Oxagen has available genetic validation data for the wide range of GPCR targets it has previously addressed. These include – GPCRs for known drug targets with already marketed products where Oxagen’s genetic association highlights alternative indications, GPCRs for drug targets that are current and known drug development targets and orphan GPCRs. Opportunities exist within the Oxagen GPCR targets for indication switches of marketed drugs or drugs in earlier stages of development. Its assets outside the field of CRTH2 antagonists are available for out-licensing.